Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 235 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle Cream Clear all
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)

NCT04845620
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
Roflumilast Cream 0.05%, Vehicle Cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years to 5 Years
Enrollment
652 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
71
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

A Study of a New Drug Treatment for Acne

NCT01326780
View directory record Official record
Conditions
Acne Vulgaris
Interventions
1.2% JNJ 10229570-AAA, 2.4% JNJ 10229570-AAA, 3.6% JNJ 10229570-AAA, Vehicle control
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
12 Years and older
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
18
States / cities
San Diego, California • Colorado Springs, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 1, 2026, 11:41 AM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

NCT05387707
View directory record Official record
Conditions
Pruritus, Atopic Dermatitis
Interventions
difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream, Placebo, Vehicle Cream
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Scottsdale, Arizona • Fort Smith, Arkansas • Rogers, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

NCT03824912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Ketoconazole Cream 2%, Ketoconazole Cream 2% (G&W Laboratories Inc.), Placebo
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Long Beach, California • Miami, Florida • Miami Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT02886715
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Tazorac®, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

Tapinarof for the Treatment of Atopic Dermatitis in Children and Adults (DMVT-505-3102)

NCT05032859
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
tapinarof cream, 1%, vehicle cream
Drug
Lead sponsor
Organon and Co
Industry
Eligibility
2 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Fort Smith, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon

NCT02688270
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Interventions
Vascana (0.9% nitroglycerin cream), Vehicle Cream (placebo)
Drug
Lead sponsor
Covis Pharma S.à.r.l.
Industry
Eligibility
18 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Multiple Locations, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

NCT03564119
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
S5G4T-1, S5G4T-2
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

NCT01400776
View directory record Official record
Conditions
Postmenopausal Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 1, 2026, 11:41 AM EDT
Recruiting Phase 2 Interventional

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07013201
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Delgocitinib cream, Vehicle cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Fountain Valley, California • Douglasville, Georgia • West Bloomfield, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris

NCT01241331
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100, Vehicle cream
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • Oceanside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

NCT01938599
View directory record Official record
Conditions
Plaque Psoriasis, Skin Diseases, Papulosquamous, Skin Diseases
Interventions
AM001 Cream, 7.5%, Placebo of AM001 Cream
Drug
Lead sponsor
AmDerma
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
5
States / cities
Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pimecrolimus Cream for Oral Lichen Planus

NCT00297037
View directory record Official record
Conditions
Oral Lichen Planus
Interventions
Pimecrolimus 1% cream
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

Three-Arm Trial of Novel Treatment for Tinea Pedis

NCT03135912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride
Drug
Lead sponsor
South End Skin Care
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

Safety, Tolerability and Efficacy of BFH772 in Rosacea Patients

NCT01449591
View directory record Official record
Conditions
Erythemato-telangiectatic Rosacea
Interventions
BFH772 1% ointment, Vehicle ointment, Noritate® 1% cream
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Hot Springs, Arkansas • Ann Arbor, Michigan • Paramus, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris

NCT03427554
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tretinoin cream 0.1%, RETIN-A® Cream, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis

NCT00384098
View directory record Official record
Conditions
Psoriasis
Interventions
CTA018 cream
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2014 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis

NCT02785185
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-122 Vehicle Lotion, IDP-122 Vehicle Cream, IDP-122 Lotion, Ultravate Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
13
States / cities
Rogers, Arkansas • Beverly Hills, California • Carlsbad, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

NCT03571620
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Q301 Cream, Vehicle
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
12 Years to 70 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 3 Interventional Results available

Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis

NCT04211389
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
ARQ-151 0.3% cream, ARQ-151 vehicle cream
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encino, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

NCT01235728
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fort Myers, Florida • Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 1 Interventional

Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease

NCT02240407
View directory record Official record
Conditions
Pompe Disease
Interventions
Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase, Rapamycin, saline, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream
Genetic · Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Sep 1, 2026, 11:41 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Sep 1, 2026, 11:41 AM EDT
Completed Phase 4 Interventional Results available

Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis

NCT00693693
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2018 · Synced Sep 1, 2026, 11:41 AM EDT